重组人血管内皮抑制素结合化疗治疗晚期非小细胞肺癌的疗效分析  

Efficacy of human recombinant endostatin combined with chemotherapy in the treatment of advanced non-small cell lung cancer

作　　者：尤江莲[1] 郭治[1] 孙爱学[1] 

机构地区：[1]河北省邢台市人民医院肿瘤内科,邢台054000

出　　处：《中国肿瘤临床与康复》2017年第6期704-707,共4页Chinese Journal of Clinical Oncology and Rehabilitation

基　　金：邢台市科学技术研究与发展计划项目(2012ZC172)

摘　　要：目的探讨重组人血管内皮抑制素结合化疗治疗晚期非小细胞肺癌的近期临床疗效。方法选取2014年8月至2016年8月间河北省邢台市人民医院收治的90例晚期非小细胞肺癌患者,采用随机数表法分为观察组与对照组,每组45例,观察组患者在培美曲塞联合顺铂化疗基础上加用重组人血管内皮抑制素治疗,对照组患者给予培美曲塞联合顺铂化疗,比较两组患者近期疗效、外周血CD4^+、CD8^+T淋巴细胞亚群水平及干预后6个月的生活质量。结果观察组患者总有效率为75.6%高于对照组患者的总有效率62.2%,两组组间比较,差异有统计学意义(P<0.05)。与治疗前比较,两组患者治疗后CD4^+升高,CD8^+降低,CD4^+/CD8^+升高,差异有统计学意义(P<0.05)。治疗后观察组患者CD4^+、CD8^+和CD4^+/CD8^+分别为(48.19±3.93)%、(28.56±5.34)%和(1.63±2.57),高于对照组患者的(44.51±4.21)%、(30.99±5.34)%和(1.40±2.23),差异均有统计学意义(均P<0.05)。与治疗前相比,两组患者治疗后生理状况、社会/家庭状况、情感状况和功能状况评分均升高,差异均有统计学意义(均P<0.05)。治疗后,观察组患者生理状况、社会/家庭状况、情感状况和功能状况评分分别为(25.72±3.90)分、(21.73±3.39)分、(20.56±3.23)分和(19.58±2.45)分,高于对照组患者的(22.56±3.93)分、(19.25±3.56)分、(18.64±3.30)分和(17.14±2.23)分,差异均有统计学意义(均P<0.05)。结论重组人血管内皮抑制素结合化疗治疗晚期非小细胞肺癌的近期临床疗效显著,能够改善患者免疫功能,提高患者生活质量。Objective To explore the short-term efficacy of human recombinant endostatin combined with chemotherapy in the treatment of advanced non-small cell lung cancer（NSCLC）. Methods Select 90 NSCLC patients treated at Xingtai People＇s Hospital from August 2014 to August 2016. Using a random number table method,patients were divided into an observation group and a control group with 45 patients in each group. Patients in the observation group were given human recombinant endostatin in addition to pemetrexed combined cisplatin chemotherapy and patients in the control group were only given pemetrexed combined cisplatin chemotherapy. Short-term efficacy,peripheral blood CD4^＋and CD8^＋,T lymphocyte subgroup and uality of life at 6 month after the intervention were compared between the two groups. Results The overall efficacy rate in the observation group（75. 6%） was higher than in the control group（62. 2%）（P〈0. 05）. Compared with before treatment,CD4^＋increased,CD8^＋decreased and CD4^＋/CD8^＋increased in both groups after treatment（P〈0. 05）. After treatment,CD4^＋,CD8^＋and CD4^＋/CD8^＋was（48. 19 ± 3. 93） %,（28. 56 ± 5. 34） % and（1. 63 ± 2. 57）,respectively for the observation group,which was higher than（44. 51 ± 4. 21） %,（30. 99 ± 5. 34） % and（1. 40 ± 2. 23）,respectively of the control group（P〈0. 05）. Scores of hysical status,social/family condition,emotional status and functional status increased in both groups after the treatment（all P〈0. 05）. To be specific,scores of hysical status,social/family condition,emotional status and functional status was（25. 72 ± 3. 90）,（21. 73 ±3. 39）,（20. 56 ± 3. 23） and（19. 58 ± 2. 45）,respectively for the observation group,which was higher than（22. 56 ± 3. 93）,（19. 25 ± 3. 56）,（18. 64 ± 3. 30） and（17. 14 ± 2. 23）,respectively of the control group after treatment（all P〈0. 05）. Conclusion Human recombinant endostatin combined with chemotherapy in treatment of adva

关 键 词：重组人血管内皮抑制素 培美曲塞 顺铂 癌 非小细胞肺 近期疗效 

分 类 号：R734.2[医药卫生—肿瘤]